Community groups, professional associations and other organizations may wish to raise money for medical research. Dalhousie Medical Research Foundation and the researchers we support are truly grateful for the efforts of such third parties to raise money for the Foundation.
If you are part of a group that would like to raise money for the Foundation, we will assist you in any way we can. The first step is to apply to the Foundation.
Click here to download the application form for Third Party Fundraising.
Ride for Dad Awards for Prostate Cancer
Ride for Dad is a prostate cancer fundraising motorcycle ride that takes place in cities across Canada each May and June. Since it began in 2000, Ride for Dad has raised $3.5 million for prostate cancer research. Prostate cancer continues to be the third leading cause of cancer deaths among Canadian men.
In 2007, Ride for Dad’s Halifax Chapter selected the Dalhousie Medical Research Foundation as its charity of choice, enabling the Foundation to award grants for prostate cancer research projects at Dalhousie Medical School.
Ride for Dad grant recipients:
Dr. Richard Wassersug, Anatomy & Neurobiology, to see if estrogen can improve sleep quality in androgen-deprived males
Androgen-deprivation is commonly used to slow the progression of advanced prostate cancer, by starving the cancer of such hormones as testosterone, which tends to drive tumour growth. Current medications can lead not only to osteoporosis, hot flashes, fatigue and cognitive impairment, but also to insomnia and sleep disturbances. Dr. Richard Wassersug is using his Ride for Dad grant to see if non-oral estrogen can improve the quantity and quality of sleep in androgen-deprived male rodents. Estrogen has already proven helpful in females and may provide an answer for men with prostate cancer who are suffering from sleep loss.
Dr. Roy Duncan, Microbiology & Immunology and Pediatrics, to explore the potential of myopodin as a marker of invasive prostate cancer
While prostate cancer is deadly when it spreads, most prostate cancers do not metastasize. Many men and their physicians therefore opt for the ‘watchful waiting’ approach, regularly monitoring the progress of the cancer to determine if steps should be taken to treat the cancer, either by radiation or by removing the prostate. Accurately reading the invasiveness of the cancer is crucial, because the treatments come with a high risk of urinary, bowel and sexual complications. Dr. Roy Duncan and his research team are exploring myopodin, a protein which is found in lower levels in invasive cancers. The researchers want to learn how myopodin is involved in or affected by prostate cancer metastasis, and if it could be used as a marker to predict how invasive a patient’s prostate cancer may be. This is vital research, because the current PSA test provides many false positives and does not predict the invasiveness of prostate cancer.